(Q47618899)

4 February 2018

title

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study (English)

1 reference

4 February 2018

metastatic renal cell carcinoma

1 reference

1 reference

5

1 reference

4 February 2018

Tomas Buchler

9

1 reference

4 February 2018

author name string

A Poprach

1

1 reference

4 February 2018

T Pavlik

2

1 reference

4 February 2018

B Melichar

3

1 reference

4 February 2018

I Puzanov

4

1 reference

4 February 2018

Z Bortlicek

6

1 reference

4 February 2018

R Vyzula

7

1 reference

4 February 2018

J Abrahamova

8

1 reference

4 February 2018

Czech Renal Cancer Cooperative Group

10

1 reference

4 February 2018

publication date

13 June 2012

1 reference

4 February 2018

published in

Annals of Oncology

1 reference

4 February 2018

volume

23

1 reference

4 February 2018

issue

12

1 reference

4 February 2018

page(s)

3137-3143

1 reference

4 February 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS145

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS145

1 reference

4 February 2018

1 reference

4 February 2018